hu1124 (Genentech).
Genentech and XOMA are collaborating in the development of a humanized monoclonal antibody, hu1124 (anti-CD11a), which has the potential to treat psoriasis and prevent organ transplant rejection. It is currently undergoing phase III clinical trials for psoriasis and phase I/II trials for transplant rejection. A phase II trial in moderate-to severe psoriasis patients was completed in January 1999 and data were initially presented at the Canadian Dermatology Association meeting in Vancouver, BC in July 1999. Following positive results from this trial, a phase III trial in moderate-to-severe psoriasis patients was initiated in December 1999. In August 1999, Genentech and XOMA expanded their collaboration to include organ transplant rejection. In March 2000, XOMA and Genentech initiated a phase I/II study of hu1124 in kidney transplant patients. In February 1999, Lehman Brothers predicted the drug had a 30% probability of reaching market. Assuming a successful launch, Lehman Brothers analysts estimated peak sales would occur in 2009 with sales at that time of 100 million USD.
Granlund
H
H
Department of Dermatology, University of Helsinki, Hiihtäjäntie 6 B 31, 00810 Helsinki, Finland. hakan.granlund@huch.fi